US 11,938,177 B2
Peptide vaccine formulations and use thereof for inducing an immune response
Robert Seder, Chevy Chase, MD (US); and Geoffrey Lynn, Bethesda, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Nov. 2, 2021, as Appl. No. 17/517,597.
Application 17/517,597 is a continuation of application No. 16/079,972, granted, now 11,191,821, previously published as PCT/US2017/019748, filed on Feb. 27, 2017.
Claims priority of provisional application 62/300,822, filed on Feb. 27, 2016.
Prior Publication US 2022/0152170 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 39/0011 (2013.01) [A61K 9/0019 (2013.01); A61K 39/001102 (2018.08); A61K 39/39 (2013.01); A61P 35/00 (2018.01); A61K 2039/555 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/60 (2013.01); A61K 2039/6093 (2013.01); B82Y 5/00 (2013.01)] 27 Claims
OG exemplary drawing
 
1. An immunogenic composition for inducing an immune response to a peptide antigen in a subject, the immunogenic composition comprising polymer nanoparticles, the polymer nanoparticles comprising:
a first polymer linked to a conjugate by an electrostatic interaction, the conjugate comprising the peptide antigen linked to a peptide tag; and
optionally an adjuvant; and
wherein
the electrostatic interaction is between the first polymer and the peptide tag;
the first polymer comprises a net negative charge and the peptide tag comprises a net positive charge at pH 7.4;
the peptide antigen from 8-12 amino acids in length or from 29-35 amino acids in length;
the peptide antigen and the conjugate are soluble in phosphate buffered saline at pH 7.4;
the peptide tag is C-terminal to the peptide antigen in the conjugate;
the peptide tag comprises 5 to 15 amino acids; and
wherein, when present, the adjuvant is a toll-like receptor 7/8 agonist and is linked to the first polymer through an amide bond; and a ratio of the adjuvant to monomer of the first polymer is from 1:100 to 1:10 mol/mol; and
wherein the polymer nanoparticles enter immune cells under physiological conditions to induce the immune response to the peptide antigen in the subject.